Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXIARO pediatric long-term immunity and booster study after primary Japanese encephalitis vaccination
2010-022265-10Phase 3
- Sponsor
- Intercell AG
- Start
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Intercell AG. Primary endpoint: Seroconversion rate at 1 month after booster.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2010-022265-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022265-10.